A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Identification of novel and effective therapies for patients who become refractory to standard anticancer treatments remains paramount. In this phase I/II study, subasumstat, a first-in-class SUMOylation inhibitor, had preliminary clinical activity and demonstrated target engagement, upregulation of IFN and plasma cytokines, and activation of innate and adaptive immune cells.
Authors
- Rafał Stec (ORCID: https://orcid.org/0000-0002-3291-6422)
- Allison Berger (ORCID: https://orcid.org/0000-0003-1217-2005)
- Armando López‐Guillermo
- John P. Gibbs (ORCID: https://orcid.org/0000-0001-8892-7318)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- José‐Ángel Hernández‐Rivas (ORCID: https://orcid.org/0000-0003-4550-757X)
- Iwona Ługowska (ORCID: https://orcid.org/0000-0001-9511-178X)
- Sławomir Mańdziuk (ORCID: https://orcid.org/0000-0002-9812-0777)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- David Schröder (ORCID: https://orcid.org/0000-0001-9588-0415)
- Dina Stroopinsky (ORCID: https://orcid.org/0009-0006-7359-1560)
- Joanna Góra‐Tybor (ORCID: https://orcid.org/0000-0002-6427-4532)
- Yuqin Song (ORCID: https://orcid.org/0000-0003-3067-5554)
- Daniel M. Anderson (ORCID: https://orcid.org/0009-0000-7229-4085)
- Feng Jung Sherida H. Woei-A-Jin (ORCID: https://orcid.org/0000-0001-7840-6156)
- Anthony J. Olszanski (ORCID: https://orcid.org/0000-0001-5276-5898)
- Marc André (ORCID: https://orcid.org/0000-0001-7101-810X)
- Tao Long (ORCID: https://orcid.org/0000-0002-0676-391X)
- Dejan Juric (ORCID: https://orcid.org/0000-0003-2983-7704)
- Bo Chao (ORCID: https://orcid.org/0009-0001-0627-8033)
- Qi Dong (ORCID: https://orcid.org/0009-0008-0291-1840)
- Aleksander Chudnovsky (ORCID: https://orcid.org/0009-0007-4961-5291)
Institutions
- Medical University of Lublin (PL)
- Fox Chase Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Pfizer (United States) (US)
- Peking University (CN)
- Medical College of Wisconsin (US)
- Rega Institute for Medical Research (BE)
- Medical University of Warsaw (PL)
- Amyotrophic Lateral Sclerosis Therapy Development Institute (US)
- Massachusetts General Hospital (US)
- CHU Dinant Godinne UCL Namur (BE)
- Peking University Cancer Hospital (CN)
- Institute of Haematology and Blood Transfusion (CZ)
- Hospital Clínic de Barcelona (ES)
- Alcide De Gasperi University of Euroregional Economy in Józefów (PL)
- Precision for Medicine (United States) (US)
- Targeted Cell Therapies (United States) (US)
- University Hospitals Seidman Cancer Center (US)
- National Institute of Oncology (HU)
- Metro-Minnesota Community Oncology Research Consortium (US)
- Takeda (United States) (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Grand Charleroi Hospital (BE)
- Hospital Universitario Infanta Leonor (ES)
- HealthPartners (US)
- Lublin University of Technology (PL)
- KU Leuven (BE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0243
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Celgene
- Relay Therapeutics
- Genentech